Verizon Boosts Profit Forecasts, Shares Hike
Verizon (NYSE:VZ) raised the lower end of its annual profit forecast on Monday, as strong demand for its higher-tier plans powered better-than-expected earnings in the second quarter. The move resulted in the company’s shares gain traction.The U.S. telecom major posted a 2.2% rise in wireless service revenue as more users opted for its add-ons such as access to streaming service like Netflix.The carrier has launched price-lock promotions and broadband-wireless bundles to retain users as competition intensifies from AT&T (NYSE:T) and T-Mobile (NASDAQ:TMUS), as well as aggressive offers from broadband providers Comcast and Charter.However, Verizon posted a surprise drop of 9,000 monthly bill-paying wireless subscribers in the April-June period, reeling from user churn after price hikes in January. Analysts were expecting an increase of 13,000 subscribers.To drive growth in the mature U.S. telecom market, Verizon and its wireless rivals have been bulking up on fiber-optic assets that can tap growing data use by customers.Overall, Verizon reported revenue of $34.5 billion, beating estimates of $33.74 billion, according to data compiled by LSEG. Its quarterly adjusted earnings per share of $1.22 also beat estimates.The company now expects 2025 adjusted profit to grow between 1% and 3%, compared with 0% to 3% previously. It also raised its annual free cash flow forecast to between $19.5 billion and $20.5 billion, from $17.5 billion to $18.5 billion.VZ shares spiked $1.53, or 3.8%, to begin Monday at $6.94.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


